This product is a second-generation sulphonylurea oral hypoglycaemic agent. It promotes insulin secretion from pancreatic beta cells and enhances insulin's action on target tissues; it also stimulates pancreatic alpha cells to inhibit glucagon secretion, while further inhibiting hepatic glycogenolysis and promoting muscle utilisation and consumption of glucose.

Primary Indications

For type II diabetes

The Main Contraindication To Medication

1. Type 1 diabetes mellitus, diabetic ketoacidosis, pre-diabetic coma or coma.

2. Contraindicated in patients with hepatic insufficiency, adrenal insufficiency, or hypersensitivity to this product.

Tablet